Adocia SA (LON:0QAI)

Market Cap	65.13M -48.8%
Revenue (ttm)	3.36M -68.3%
Net Income	-14.47M
EPS	-0.81
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Open	3.970
Previous Close	3.948
Day's Range	3.934 - 3.970
52-Week Range	3.690 - 12.240
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 73
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAI

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 9, 2026

Data Sources Report a data error